Nuvation Bio Inc. (NUVB)

Market Cap	350.66M
Revenue (ttm)	n/a
Net Income (ttm)	-104.20M
Shares Out	217.80M
EPS (ttm)	-0.48
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	234,149
Open	1.59
Previous Close	1.61
Day's Range	1.59 - 1.66
52-Week Range	1.55 - 6.02
Beta	0.66
Analysts	Buy
Price Target	4.04 (+150.93%)
Earnings Date	May 8, 2023

About NUVB

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an ad...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 54
• Stock Exchange: NYSE
• Ticker Symbol: NUVB

Analyst Forecast

According to 13 analysts, the average rating for NUVB stock is "Buy." The 12-month stock price forecast is $4.04, which is an increase of 150.93% from the latest price.

Price Target

$4.04

(150.93% upside)

Analyst Consensus: Buy